Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : New Findings from Regeneron Pharmaceuticals Inc. Describe Advances in General Science (microTSS: accurate microRNA transcription start site...

01/29/2015 | 02:26pm US/Eastern

New Findings from Regeneron Pharmaceuticals Inc. Describe Advances in General Science (microTSS: accurate microRNA transcription start site identification reveals a significant number of divergent pri-miRNAs)

By a News Reporter-Staff News Editor at Science Letter -- Investigators publish new report on Science. According to news originating from Tarrytown, New York, by NewsRx correspondents, research stated, "A large fraction of microRNAs (miRNAs) are derived from intergenic non-coding loci and the identification of their promoters remains 'elusive'. Here, we present microTSS, a machine-learning algorithm that provides highly accurate, single-nucleotide resolution predictions for intergenic miRNA transcription start sites (TSSs)."

Our news journalists obtained a quote from the research from Regeneron Pharmaceuticals Inc., "MicroTSS integrates high-resolution RNA-sequencing data with active transcription marks derived from chromatin immunoprecipitation and DNase-sequencing to enable the characterization of tissue-specific promoters. MicroTSS is validated with a specifically designed Drosha-null/conditional-null mouse model, generated using the conditional by inversion (COIN) methodology. Analyses of global run-on sequencing data revealed numerous pri-miRNAs in human and mouse either originating from divergent transcription at promoters of active genes or partially overlapping with annotated long non-coding RNAs."

According to the news editors, the research concluded: "MicroTSS is readily applicable to any cell or tissue samples and constitutes the missing part towards integrating the regulation of miRNA transcription into the modelling of tissue-specific regulatory networks."

For more information on this research see: microTSS: accurate microRNA transcription start site identification reveals a significant number of divergent pri-miRNAs. Nature Communications, 2014;5():117-127. Nature Communications can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Nature Communications - www.nature.com/ncomms/)

The news correspondents report that additional information may be obtained from G. Georgakilas, Regeneron Pharmaceut Inc, Tarrytown, NY 10591, United States. Additional authors for this research include I.S. Vlachos, M.D. Paraskevopoulou, P. Yang, Y.H. Zhang, A.N. Economides and A.G. Hatzigeorgiou (see also Science).

Keywords for this news article include: Science, New York, Tarrytown, United States, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC

(c) 2015 NewsRx LLC

React to this article
Latest news on REGENERON PHARMACEUTICALS
01/29 REGENERON PHARMACEUTICALS : New Findings from Regeneron Pharmaceuticals Inc. Des..
01/28 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Recommended for Approva..
01/27DJAmgen Profit Rises 27% on Higher Sales of Key Drugs -- Update
01/27 Investing in Westchester's biotech surge
01/27 SANOFI : and Regeneron Announce Praluent (alirocumab) Biologics License Applicat..
01/26DJSANOFI : FDA Grants Priority Review for Sanofi and Regeneron's Drug
01/26 REGENERON PHARMACEUTICALS : and Sanofi Announce Praluent™ (alirocumab) Bio..
01/23 REGENERON PHARMACEUTICALS : New Data from Regeneron Pharmaceuticals Inc. Illumin..
01/23 REGENERON PHARMACEUTICALS : Details Findings in Immunoglobulins (Efficacy and sa..
01/23 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Recommended for Appro..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF